SOAT1 and neoplasm: Preclinical evidence has shown that IL6 enhances tumor cell survival and increases resistance to chemotherapy via JAK/STAT signaling in tumor cells [7] and IL6 receptor alpha trans-signaling on tumor endothelial cells [8,9].